Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$18,373 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
11.6
Industry P/E
--
EV/EBITDA
-9.7
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$8.6
EPS
$-6
Face value
--
Shares outstanding
198,173,397
CFO
$-895.77 Mln
EBITDA
$-1,140.87 Mln
Net Profit
$-1,093.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Revolution Medicines (RVMD)
| 23.8 | -3.3 | 23.8 | 179.0 | 65.8 | 16.5 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Revolution Medicines (RVMD)
| 82.1 | 52.0 | 20.4 | -5.4 | -36.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Revolution Medicines (RVMD)
|
98.6 | 18,372.7 | 0.0 | -1,131.3 | -- | -58.1 | -- | 11.6 |
| 0.0 | 0.0 | 0.0 | -31.6 | -- | -- | -- | 2.3 | |
| 0.0 | 0.1 | 0.0 | -12.4 | -65,168.4 | -147.7 | -- | 0.0 | |
| 1.9 | 20.3 | 0.0 | -27.7 | -640,975.0 | -240.9 | -- | 1.3 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as... monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Address: 700 Saginaw Drive, Redwood City, CA, United States, 94063 Read more
CEO, President & Chairman
Dr. Mark A. Goldsmith Ph.D.
CEO, President & Chairman
Dr. Mark A. Goldsmith Ph.D.
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Revolution Medicines Inc (RVMD) is $98.64 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Revolution Medicines Inc (RVMD) has given a return of 65.75% in the last 3 years.
Since, TTM earnings of Revolution Medicines Inc (RVMD) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-13.38
|
9.28
|
|
2024
|
-12.25
|
3.24
|
|
2023
|
-7.43
|
1.77
|
|
2022
|
-7.76
|
2.82
|
|
2021
|
-9.82
|
3.05
|
The 52-week high and low of Revolution Medicines Inc (RVMD) are Rs 124.49 and Rs 29.17 as of 02-Apr-2026.
Revolution Medicines Inc (RVMD) has a market capitalisation of $ 18,373 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Revolution Medicines Inc (RVMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$1.39
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.